Myrexis (MYRX) to Review Strategic Alternatives
Tweet
Share
E-mail
Myrexis, Inc. (Nasdaq: MYRX), announced that its Board of Directors has retained Stifel Nicolaus Weisel, an investment banking firm, to assist it in reviewing and evaluating a full range of strategic alternatives available to the Company to enhance shareholder value.
Myrexis has also suspended development activities on all its pre-clinical and clinical programs. The Company will initiate an alignment of resources consistent with its decision to suspend further development activities.
The Company is committed to conducting its review of potential alternatives as promptly as practicable. However, there can be no assurances that any particular alternative will be pursued or that any transaction will occur, or on what terms or as to its timing. Myrexis intends to provide additional information as appropriate.
Myrexis has also suspended development activities on all its pre-clinical and clinical programs. The Company will initiate an alignment of resources consistent with its decision to suspend further development activities.
The Company is committed to conducting its review of potential alternatives as promptly as practicable. However, there can be no assurances that any particular alternative will be pursued or that any transaction will occur, or on what terms or as to its timing. Myrexis intends to provide additional information as appropriate.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Real and RE/MAX Holdings receive court approval for merger
- Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
- Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
Create E-mail Alert Related Categories
Corporate News, Mergers and Acquisitions, Trading HaltsRelated Entities
StifelSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
